Alvotech Begins Trading on Nasdaq Stockholm, Expands Nordic Presence
Alvotech, the Icelandic biopharmaceutical company specialising in developing and manufacturing biosimilar medicines, began trading today on Nasdaq Sto...
Alvotech Poised for Rapid Growth Following Nasdaq Listing
Alvotech, the Icelandic biopharmaceutical company specialising in biosimilars, is anticipating significant growth following its recent listing on the ...
Alvotech and STADA Pave Way partner together
Alvotech, an Iceland-based global biopharmaceutical company, has announced that all intellectual property disputes with AbbVie related to its AVT02 bi...
New leadership at Actavis pharmaceuticals
Actavis has announced a number of senior appointments at the international generic drugs company. Gudbjorg Edda Eggertsdottir has been appointed as De...
Actavis CEO steps down
Robert Wessman has today stepped down as the CEO of Actavis, one of the world’s leading international generic drug companies. He will be replaced by t...
Robert Wessman to speak at UBS pharmaceuticals conference
The CEO of Actavis generic pharmaceuticals, Robert Wessman, is scheduled to speak at the annual UBS Global Specialty and Generic Pharmaceuticals Confe...
Harvard publishes case study on Actavis pharmaceuticals
Actavis, a generic pharmaceuticals company based in Iceland, last week announced that Harvard Business School had produced a case study on the company...